Inhibrx Biosciences, Inc.

Inhibrx Biosciences, Inc. is a U.S.-based clinical-stage biotechnology company focused on developing antibody-based therapeutics. Following the 2024 separation from its former parent, the company now centers on ozekibart (INBRX-109) and INBRX-106, with additional discovery-stage programs and no approved commercial products yet.

−10 195,5 %

−10 773,5 %

+550,0 %

3.93

3.93

— Inhibrx Biosciences, Inc.
%
Clinical-stage therapeutic candidates0% Includes ozekibart (INBRX-109) and INBRX-106, which are being advanced through clinical trials.
Discovery pipeline0% Early-stage biologic programs and research assets not yet in clinical development.
License and collaboration revenue100% Non-product revenue recognized from licensing and assignment agreements with partners.
Outsourced development operations0% Clinical, manufacturing, and research activities managed through third-party CROs and CDMOs.

The company does not sell approved products commercially, so its current counterparties are primarily licensing...

  • Licensing and collaboration partnersprimary

    Buy rights to programs or provide upfront/option payments tied to asset access and development milestones.

  • CRO and CDMO service providersprimary

    Support preclinical studies, clinical trials, and manufacturing scale-up for the company's pipeline.

  • Future healthcare providers and patientsemerging

    Would use the company's therapies if any candidate reaches approval and commercialization.

  • Strategic acquirers or monetization partnersemerging

    Potential buyers of ozekibart or other assets in transactions intended to unlock value.

The company is headquartered in the United States and its operations are primarily U.S...

  • •Headquartered in the United States
  • •Clinical and corporate operations are primarily U.S.-based
  • •No disclosed country-level revenue concentration in the excerpts
  • •Outsourced manufacturing and trial supply chains may span multiple countries
  • •U.S. tariffs and trade policy can affect input costs and supply continuity

Management is focused on advancing INBRX-106 through clinical development while evaluating alternatives to monetize...

01
Advance INBRX-106 clinical programshort-term

Clinical data is the main value driver for a pre-commercial biotech and determines future partnering or approval prospects.

02
Monetize ozekibart (INBRX-109)short-term

A transaction could unlock value and reduce dependence on internal funding while minimizing dilution.

03
Preserve capital and operational flexibilitymedium-term

The company has no product revenue and relies on external financing to fund R&D and corporate overhead.

The company faces the typical risks of a clinical-stage biotech: trial failure, regulatory setbacks, and the need for...

high

Clinical development and regulatory failure

INBRX-106 and ozekibart are still clinical-stage, so negative data or regulatory setbacks could materially reduce value.

Scope
Phase 2/3 oncology and biologics development
Materiality
high
high

Dependence on third-party manufacturers and CROs/CDMOs

The company does not own manufacturing facilities and relies on a limited number of external providers for raw materials and clinical supply.

Scope
Clinical trial supply, biologics manufacturing, scale-up
Materiality
high
high

Financing and dilution risk

With no commercial product revenue, the company may need additional capital to fund ongoing R&D and operations.

Scope
Cash runway, debt, equity issuance
Materiality
high
medium

Ozekibart monetization uncertainty

A transaction may not occur, may take longer than expected, or may not deliver the intended tax or value benefits.

Scope
Strategic transaction execution
Materiality
medium
medium

Tariffs and geopolitical supply-chain disruption

Higher import costs or supply interruptions could affect biologic raw materials and clinical trial continuity.

Scope
Global sourcing and manufacturing inputs
Materiality
medium
License fee revenue recognition
Can create lumpy quarterly revenue from collaboration agreements
Research and development expense timing
Quarterly operating loss can swing with study activity and vendor timing
Lease commitments
Affects right-of-use assets, lease liabilities, and cash commitments
Debt and interest expense
Impacts liquidity, leverage, and net loss

Inhibitor Therapeutics, Inc.

INTI · Pharmaceutical Preparations

Inhibikase Therapeutics, Inc.

IKT · Biological Products, (No Diagnostic Substances)

BiomX Inc.

PHGE · Biological Products, (No Diagnostic Substances)

Innoviva, Inc.

INVA · Pharmaceutical Preparations

Instil Bio, Inc.

TIL · Biological Products, (No Diagnostic Substances)

IMMUNIC, INC.

IMUX · Pharmaceutical Preparations

: 28.4.2026